{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-055918","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.413693+00:00","generated_at":"2026-06-26T00:32:07.676883+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Protagonist reports Q1 net loss $20.9M; initiates rusfertide Phase 3 VERIFY in PV","bullets":["Q1 2022 net loss $20.9M ($0.43 per share) vs $24.0M ($0.54) in Q1 2021.","License and collaboration revenue $25.7M, including $25M milestone from Janssen for PN-235.","Cash and securities $305.3M; runway through end of 2024.","Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera; enrollment completion expected 1H 2023.","Phase 2 IDEAL study of PN-943 in UC met proof-of-concept at 150 mg BID; engaged PJT Partners for partnering."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-055918","json":"https://secwatch.observer/filing/0001104659-22-055918.json","markdown":"https://secwatch.observer/filing/0001104659-22-055918.md","text":"https://secwatch.observer/filing/0001104659-22-055918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922055918/0001104659-22-055918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922055918/tm2214413d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:32:07.676883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}